SCHEMBL19987173

SCHEMBL19987173

CC(C)OC[C@H](C)NP(=O)(OC[C@H]1O[C@@H](n2cnc3c(N)ncnc32)C(F)C1(C)CCN)Oc1ccccc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
P2RY12 Q9H244 5/20 0.39
P2RY2 P41231 3/20 0.38
P2RY1 P47900 2/20 0.38
P2RX3 P56373 4/20 0.38
P2RX4 Q99571 4/20 0.38
P2RX1 P51575 1/20 0.38
P2RX2 Q9UBL9 1/20 0.38
NT5E P21589 2/20 0.37
DNPH1 O43598 1/20 0.37
PRKAB2 O43741 1/20 0.37
TRPM2 O94759 1/20 0.37
LDHA P00338 1/20 0.37
ADRB2 P07550 1/20 0.37
FBP1 P09467 1/20 0.37
SRC P12931 1/20 0.37
ADORA1 P30542 1/20 0.37
PRKAG1 P54619 1/20 0.37
PRKAA2 P54646 1/20 0.37
PDE4D Q08499 1/20 0.37
KCNH2 Q12809 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19987164 0.89 CYP3A4 (0.44) P2RY12P2RY2P2RY1P2RX3P2RX4
SCHEMBL19987288 0.83 CYP3A4 (0.44) P2RY12P2RY2P2RY1P2RX3P2RX4
SCHEMBL19987167 0.82 CYP3A4 (0.43) P2RY12P2RX3P2RX4P2RX2DNPH1
SCHEMBL19987260 0.81 P2RY12 (0.39) P2RY12P2RY2P2RY1P2RX3P2RX4
SCHEMBL21511161 0.80 CYP3A4 (0.43) P2RY12P2RY2P2RY1P2RX3P2RX4
SCHEMBL21511203 0.79 CYP3A4 (0.40)
SCHEMBL19987222 0.75 CYP3A4 (0.43) P2RY12P2RX3P2RX4P2RX1P2RX2
SCHEMBL19987308 0.74 CYP3A4 (0.45) P2RY12DNPH1
SCHEMBL21511201 0.74 CYP3A4 (0.45) P2RY12DNPH1
SCHEMBL19987218 0.74 CYP3A4 (0.45) P2RY12DNPH1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2018049535-A1 NUCLEOSIDE ANALOGUES AND METHODS OF USE THEREOF LCB PHARMA INC. (CA) 2018-03-22 WO disclosed